Maintenance treatment for advanced stomach cancer in Colombia
Part of Cancer, Digestive system clinical trials.
This study looks at people with advanced stomach cancer who received a maintenance treatment after initial therapy. The goal is to see how well this approach works in real-world patients in Colombia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were diagnosed with stomach cancer that has spread to other parts of the body between 2013 and 2023.
- You received a maintenance treatment called fluoropyrimidine (a type of chemotherapy) after your initial treatment, and possibly also immunotherapy or targeted therapy.
- Your cancer was stable or better after your initial treatment, and you were in good enough health to continue treatment.
- You had regular check-ups at the same hospital as part of your cancer care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at patients with stomach cancer who received a combination of chemotherapy drugs (called FLOT) before and after surgery. It aims to see how well the treatment works and what side effects patients may have.
This trial tests a combination of two drugs, fruquintinib and a PD-1 inhibitor, as maintenance treatment after initial chemotherapy for advanced stomach or gastroesophageal junction cancer. It aims to see if this maintenance approach helps keep the cancer from growing. It is for patients with stable disease or better after first-line therapy.
This trial compares two approaches for people with stomach cancer that has spread: having surgery to remove the cancer after a course of 'translational therapy' (a treatment to shrink the tumor), or continuing with standard maintenance chemotherapy. The goal is to see which approach helps people live longer and feel better.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.